May 13th 2024
Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to control bleeding.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More
Cognitive Training Programs Have No Long-Term Benefit for Children Born Very Preterm
September 13th 2023Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.
Read More
Preventing Respiratory Syncytial Virus at a Young Age May Reduce Risk of Developing Asthma
September 12th 2023Pediatric and maternal respiratory syncytial virus (RSV) vaccines are being studied to reduce the burden of RSV, and more research is needed to understand whether this can reduce wheeze and asthma.
Read More
Potential Associations Found Between Microbiome, Early Cognitive Development in Infants
August 16th 2023Key study finding shows associations between the beat frequency in the rhythmic stimulus in the frontal left sites of infant brains and pathways related to brain modulation and nucleotide levels.
Read More